Form 8-K - Current report:
SEC Accession No. 0001193125-24-235598
Filing Date
2024-10-10
Accepted
2024-10-10 07:16:01
Documents
17
Period of Report
2024-10-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d877681d8k.htm   iXBRL 8-K 37756
2 EX-4.1 d877681dex41.htm EX-4.1 13323
3 EX-99.1 d877681dex991.htm EX-99.1 11612
8 GRAPHIC g877681g1010033741024.jpg GRAPHIC 8267
  Complete submission text file 0001193125-24-235598.txt   245458

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tpst-20241007.xsd EX-101.SCH 3349
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tpst-20241007_def.xml EX-101.DEF 13624
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20241007_lab.xml EX-101.LAB 22653
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20241007_pre.xml EX-101.PRE 14402
19 EXTRACTED XBRL INSTANCE DOCUMENT d877681d8k_htm.xml XML 5856
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 241363819
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)